Octapharma USA today announced the first grant recipient of the Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center. The Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine. Leonard A. Valentino, M.D., Director of the Section of Pediatric Hematology-Oncology and the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center, is the lead investigator for this research effort. Dr. Valentino, a physician with nearly 20 years experience with bleeding and clotting disorders, will study the impact of age at the time of first hemarthrosis on the development of arthropathy. Dr. Valentino leads one of the largest pediatric hemophilia and thrombophilia centers in the United States as well as an active basic and translational science research group. His research focus has been on the causes and mechanisms of blood induced joint disease.

Octapharma AG, one of the largest human protein products manufacturers in the world, launched the Octapharma Grants program last year in celebration of the biopharmaceutical company’s 25th anniversary. The company’s first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA, the Swiss company’s rapidly-growing U.S. subsidiary.

Image by MorgueFile.com via Free License.